Oncology News & Perspectives

Featured Exclusive

In this exclusive with i3 Health, Craig H. Moskowitz, MD, Professor of Medicine at the University of Miami and Physician-in-Chief at the Sylvester Comprehensive Cancer Center, and Kami Maddocks, MD, Associate Professor of Clinical Internal Medicine and Lymphoma Program Director at The James Cancer Hospital at The Ohio State University, share their perspectives on the manage...

Top Oncology Stories

Friday, November 15, 2019
The FDA has approved zanubrutinib (Brukinsa®, BeiGene) for patients with relapsed/refractory mantle cell lymphoma (MCL) who have received at least one previous therapy.The a...
Thursday, November 14, 2019
​A new study has utilized data to determine the ages at which women with various degrees of familial history of breast cancer should begin screening. Breast cancer is a se...
Wednesday, November 13, 2019
​In previously untreated chronic lymphocytic leukemia (CLL), acalabrutinib (Calquence®, AstraZeneca) improves progression-free survival either as monotherapy or in combination ...
Tuesday, November 12, 2019
​Twelve-year follow-up results of the HOVON-65/GMMG-HD4 study reveal that among transplant-eligible patients with newly diagnosed multiple myeloma, those with renal impairment ...
Monday, November 11, 2019
According to a recent phase 2 study, denosumab is an effective treatment for patients with giant-cell tumor of bone (GCTB).In this study, results of which are published in T...

Expert Perspectives

In this exclusive with i3 Health, Craig H. Moskowitz, MD, Professor of Medicine at the University of Miami and Physician-in-Chief at the Sylvester Comprehensive Cancer Center, and Kami Maddocks, MD, Associate Professor of Clin...
​Ibrutinib is an effective treatment for several B-cell malignancies, including mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenstrom macroglobulinemia. However, it can cause cardiotoxicity. Under the direction o...
​Biliary tract cancers have a dismal prognosis, with five-year survival rates ranging from 5% to 15%. In their publication in JAMA Oncology, Sarah S. Jackson, PhD, and colleagues report that aspirin increases survival in bilia...
Gregg L. Semenza, MD, PhD, was recently awarded the Nobel Prize in Physiology or Medicine for his groundbreaking work in isolating hypoxia inducible factor (HIF) 1, which controls genes that are involved in cells' adaptation t...
In combination with exemestane, everolimus is an effective treatment for estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. However, this treatment can often ...

Original Research

Pre-activity assessment data from i3 Health's continuing medical education (CME)/continuing nursing education (CNE) activity "Optimizing the Management of Advanced Cervical Cancer With Checkpoint Inhibitor Therapy" has reveale...
Due to the increase in treatment options for castration-resistant prostate cancer (CRPC) in recent years, some confusion exists over the optimal therapeutic approach. A number of factors must be considered in CRPC treatment...
Optimal management of carcinoid syndrome in patients with neuroendocrine tumors poses a challenge, due to the fact that the primary symptoms of carcinoid syndrome are associated with more common diseases. Because timely rec...
As the number of treatments for recurrent ovarian cancer expands, confusion may develop over which therapeutic strategy is best to use. Numerous patient factors need to be taken into account when deciding on a treatment plan, such...
​In the constantly evolving field of cancer immunotherapy, it is crucial that community practitioners keep abreast of the latest advances. In this interview with i3 Health, Latha Shivakumar, PhD, CHCP, discusses her poster pre...

© Copyright 2019 i3 Health. All rights reserved.